Cowpea mosaic virus as a vaccine carrier of heterologous antigens

The plant virus, cowpea mosaic virus (CPMV), has been developed as an expression and presentation system to display antigenic epitopes derived from a number of vaccine targets including infectious disease agents and tumors. These chimeric virus particles (CVPs) could represent a cost-effective and safe alternative to live replicating virus and bacterial vaccines. A number of CVPs have now been generated and their immunogenicity examined in a number of animal species. This review details the humoral and cellular immune responses generated by these CVPs following both parenteral and mucosal delivery and highlights the potential of CVPs to elicit protective immunity from both viral and bacterial infection.

[1]  A. Heimdahl,et al.  Experimental endocarditis in the rat secondary to septic arthritis induced by Staphylococcus aureus. , 1999, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  G. Lomonossoff,et al.  Cauliflower mosaic virus 35S promoter-controlled DNA copies of cowpea mosaic virus RNAs are infectious on plants. , 1993, The Journal of general virology.

[3]  H. Kiyono,et al.  Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate , 1995, Nature Medicine.

[4]  T. Hill,et al.  Enhancement of the immune response to non-replicating herpes simplex virus type-1 preparations by mucosal administration in the presence of cholera toxin. , 1997, Vaccine.

[5]  M. Estes,et al.  Oral Immunization with Recombinant Norwalk Virus-Like Particles Induces a Systemic and Mucosal Immune Response in Mice , 1998, Journal of Virology.

[6]  R. Boshuizen,et al.  Plant–derived vaccine protects target animals against a viral disease , 1997, Nature Biotechnology.

[7]  G. Dougan,et al.  Live Salmonella vaccines as a route towards oral immunisation. , 1995, Biologicals : journal of the International Association of Biological Standardization.

[8]  M. Borca,et al.  Isotype profiles induced in Balb/c mice during foot and mouth disease (FMD) virus infection or immunization with different FMD vaccine formulations. , 1995, Vaccine.

[9]  F. Brennan,et al.  Antibodies that block adherence of Staphylococcus aureus to fibronectin , 1999 .

[10]  W. Hamilton,et al.  Immunogenicity of peptides derived from a fibronectin-binding protein of S. aureus expressed on two different plant viruses. , 1999, Vaccine.

[11]  A. Wong,et al.  A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. , 1997, Cancer research.

[12]  P. Humphrey,et al.  Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R. Berg,et al.  Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice , 1984, Infection and immunity.

[14]  D. Gochnour,et al.  Clinical and immunological effects of a synthetic Beta-human chorionic-gonadotropin vaccine. , 1994, International journal of oncology.

[15]  H. Stauss.  Mutant Ras proteins and peptides: bad news for tumors. , 1995, Journal of the National Cancer Institute.

[16]  M. Lindberg,et al.  Cloning and expression of the gene for a fibronectin‐binding protein from Staphylococcus aureus. , 1987, The EMBO journal.

[17]  E. Beachey,et al.  Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model , 1988, Infection and immunity.

[18]  P. Bruggen,et al.  Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.

[19]  J. Wharton,et al.  Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro. , 1994, Cellular immunology.

[20]  C. Parrish.  Emergence, Natural History, and Variation of Canine, Mink, and Feline Parvoviruses , 1990, Advances in Virus Research.

[21]  G. Lomonossoff,et al.  Use of viral replicons for the expression of genes in plants , 1996, Molecular biotechnology.

[22]  R. Levy,et al.  Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. , 1986, Journal of immunology.

[23]  R. N. Harty,et al.  A Chimeric Influenza Virus Expressing an Epitope of Outer Membrane Protein F of Pseudomonas aeruginosa Affords Protection against Challenge with P. aeruginosa in a Murine Model of Chronic Pulmonary Infection , 1998, Infection and Immunity.

[24]  E E Hughes,et al.  Ability of synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa to afford protection against P. aeruginosa infection in a murine acute pneumonia model. , 1995, Vaccine.

[25]  J. Taylor‐Papadimitriou,et al.  A short sequence, within the amino acid tandem repeat of a cancer‐associated mucin, contains immunodominant epitopes , 1989, International journal of cancer.

[26]  Z. Fu,et al.  Immunization against rabies with plant-derived antigen. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Goldbach,et al.  Structure, replication and expression of the bipartite genome of cowpea mosaic virus , 1985 .

[28]  A. Hill,et al.  A protein particle vaccine containing multiple malaria epitopes , 1997, Nature Biotechnology.

[29]  A. Abbas,et al.  Stability of Th1 and Th2 populations. , 1995, International immunology.

[30]  N. Dimmock,et al.  Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide. , 1999, Vaccine.

[31]  C. Partidos,et al.  Induction of systemic immune responses to measles virus synthetic peptides administered intranasally. , 1995, Vaccine.

[32]  S. Dirnhofer,et al.  The suitability of human chorionic gonadotropin (hCG)-based birth-control vaccines. , 1994, Immunology today.

[33]  N. Dimmock,et al.  Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160. , 1994, AIDS research and human retroviruses.

[34]  N. Dimmock,et al.  Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. , 1998, Journal of immunological methods.

[35]  G. V. van Dam,et al.  Nonionic block polymer surfactants modulate the humoral immune response against Streptococcus pneumoniae-derived hexasaccharide-protein conjugates , 1989, Infection and immunity.

[36]  M. Pepys,et al.  Activation of mouse complement by different classes of mouse antibody. , 1979, Immunology.

[37]  C. Alving,et al.  Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. , 1993, Immunobiology.

[38]  B. Sherry,et al.  Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14 , 1986, Journal of virology.

[39]  T. Chang,et al.  Structural features of the extracellular portion of membrane-anchoring peptides on membrane-bound immunoglobulins. , 1996, Molecular immunology.

[40]  M. Marinaro,et al.  Mucosal immunity to infection with implications for vaccine development. , 1994, Current opinion in immunology.

[41]  D. Knipe,et al.  Mechanism of virus-induced Ig subclass shifts. , 1994, Journal of immunology.

[42]  R. Levy,et al.  Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. , 1992, The New England journal of medicine.

[43]  P. Messner,et al.  Bet v 1, the major birch pollen allergen, conjugated to crystalline bacterial cell surface proteins, expands allergen-specific T cells of the Th1/Th0 phenotype in vitro by induction of IL-12. , 1997, International immunology.

[44]  A. Osterhaus,et al.  First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs , 1994, Journal of virology.

[45]  C. Leclerc,et al.  Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Lotze,et al.  A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. , 1996, The Journal of surgical research.

[47]  G. Gros,et al.  The role of Th2 type CD4+ T cells and Th2 type CD8+ T cells in asthma , 1996, Immunology and cell biology.

[48]  D. J. Evans,et al.  Poliovirus antigen chimeras. , 1991, Trends in biotechnology.

[49]  R. Coffman,et al.  Regulation of immunity to parasites by T cells and T cell-derived cytokines. , 1992, Annual review of immunology.

[50]  John E. Johnson,et al.  Expression of an animal virus antigenic site on the surface of a plant virus particle. , 1993, Virology.

[51]  J. Shiver,et al.  Protein expression in vivo by injection of polynucleotides. , 1994, Current opinion in biotechnology.

[52]  C. Nathan,et al.  Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma. , 1985, Journal of immunology.

[53]  A. Delmas,et al.  Linkage of a fusion peptide to a CTL epitope from the nucleoprotein of measles virus enables incorporation into ISCOMs and induction of CTL responses following intranasal immunization. , 1996, Vaccine.

[54]  R. Kennedy,et al.  Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein. , 1986, Science.

[55]  E. Arnold,et al.  Chimeras from a human rhinovirus 14-human immunodeficiency virus type 1 (HIV-1) V3 loop seroprevalence library induce neutralizing responses against HIV-1 , 1995, Journal of virology.

[56]  K. Lloyd,et al.  Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. , 1996, Cancer research.

[57]  B Poutrel,et al.  Virulence factors involved in the pathogenesis of bovine intramammary infections due to Staphylococcus aureus. , 1994, Journal of medical microbiology.

[58]  M. Lindberg,et al.  Vaccination against Staphylococcus aureus mastitis: immunological response of mice vaccinated with fibronectin-binding protein (FnBP-A) to challenge with S. aureus. , 1994, Vaccine.

[59]  K. Lövgren,et al.  An experimental influenza subunit vaccine (iscom): induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration , 1990, Clinical and experimental immunology.

[60]  H. E. Gilleland,et al.  Synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa that elicit antibodies reactive with whole cells of heterologous immunotype strains of P. aeruginosa , 1992, Infection and immunity.

[61]  John E. Johnson,et al.  Structure-based design of peptide presentation on a viral surface: the crystal structure of a plant/animal virus chimera at 2.8 A resolution. , 1996, Folding & design.

[62]  D. Rahman,et al.  Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. , 1992, Immunology.

[63]  Kensil Cr.  Saponins as vaccine adjuvants. , 1996 .

[64]  P. Ciborowski,et al.  Immunological response to a Staphylococcus aureus fibronectin-binding protein. , 1992, Journal of medical microbiology.

[65]  J. Johnson,et al.  The synthesis and structure of comovirus capsids. , 1991, Progress in biophysics and molecular biology.

[66]  B. Moss,et al.  Nonreplicating vaccinia vector efficiently expresses recombinant genes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[67]  H. Staats,et al.  Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). , 1996, Journal of immunology.

[68]  H. Grey,et al.  Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line , 1977, The Journal of experimental medicine.

[69]  J. Johnson,et al.  Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus. , 1999, Microbiology.

[70]  H. E. Gilleland,et al.  Synthetic peptides representing two protective, linear B-cell epitopes of outer membrane protein F of Pseudomonas aeruginosa elicit whole-cell-reactive antibodies that are functionally pseudomonad specific , 1995, Infection and immunity.

[71]  R. Coffman,et al.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. , 1986, Journal of immunology.

[72]  John E. Johnson,et al.  Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides. , 1994, Virology.

[73]  W. Hamilton,et al.  Chimeric Plant Virus Particles Administered Nasally or Orally Induce Systemic and Mucosal Immune Responses in Mice , 1999, Journal of Virology.

[74]  A. Heimdahl,et al.  Immunization with fibronectin binding protein from Staphylococcus aureus protects against experimental endocarditis in rats. , 1993, Microbial pathogenesis.

[75]  R. Meloen,et al.  Characterization and primary structure of a human immunodeficiency virus type 1 (HIV-1) neutralization domain as presented by a poliovirus type 1/HIV-1 chimera. , 1993, The Journal of general virology.

[76]  A. Kingsman,et al.  The expression of hybrid HIV:Ty virus-like particles in yeast , 1987, Nature.

[77]  J. Snick,et al.  IgG2a restriction of murine antibodies elicited by viral infections , 1987, The Journal of experimental medicine.

[78]  J. Kirkwood,et al.  New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines , 1996, Melanoma research.

[79]  G. Lomonossoff,et al.  Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus. , 1996, Vaccine.

[80]  M. Estes,et al.  Rotavirus virus-like particles administered mucosally induce protective immunity , 1997, Journal of virology.

[81]  A. Townsend,et al.  Antigen recognition by class I-restricted T lymphocytes. , 1989, Annual review of immunology.

[82]  W. Paul,et al.  Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. , 1987, Science.

[83]  D. MacGlashan,et al.  Monoclonal Antibodies Specific for Human IgE-Producing B Cells: A Potential Therapeutic for IgE-Mediated Allergic Diseases , 1990, Bio/Technology.

[84]  W. Hamilton,et al.  A chimaeric plant virus vaccine protects mice against a bacterial infection. , 1999, Microbiology.

[85]  D. Wechsler,et al.  Heat-labile IgG2a antibodies affect cure of Trypanosoma musculi infection in C57BL/6 mice. , 1986, Journal of immunology.

[86]  J. Bidart,et al.  The molecular basis for epitopes on the free beta-subunit of human chorionic gonadotrophin (hCG), its carboxyl-terminal peptide and the hCG beta-core fragment. , 1994, The Journal of endocrinology.

[87]  M. Lindberg,et al.  Nucleotide sequence of the gene for a fibronectin-binding protein from Staphylococcus aureus: use of this peptide sequence in the synthesis of biologically active peptides. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[88]  A. Almeida,et al.  Nasal delivery of vaccines. , 1996, Journal of drug targeting.

[89]  G. Lomonossoff,et al.  Human immunodeficiency virus type 1-neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus. , 1995, AIDS research and human retroviruses.

[90]  S. Ishizaka,et al.  IgG subtype is correlated with efficiency of passive protection and effector function of anti-herpes simplex virus glycoprotein D monoclonal antibodies. , 1995, The Journal of infectious diseases.

[91]  R. Hunter,et al.  Multiple antigen constructs (MACs): induction of sterile immunity against sporozoite stage of rodent malaria parasites, Plasmodium berghei and Plasmodium yoelii. , 1997, Vaccine.